Currently, there are 6.58M common shares owned by the public and among those 5.44M shares have been available to trade.
The company’s stock has a 5-day price change of 30.12% and -70.98% over the past three months. MTEM shares are trading -87.86% year to date (YTD), with the 12-month market performance down to -91.33% lower. It has a 12-month low price of $0.29 and touched a high of $5.45 over the same period. MTEM has an average intraday trading volume of 9.43 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.54%, -50.08%, and -72.57% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Molecular Templates Inc (NASDAQ: MTEM) shares accounts for 40.94% of the company’s 6.58M shares outstanding.
It has a market capitalization of $2.29M and a beta (3y monthly) value of 1.15. The earnings-per-share (ttm) stands at -$2.70. Price movements for the stock have been influenced by the stock’s volatility, which stands at 67.38% over the week and 23.39% over the month.
EPS should shrink at an annualized rate of 3.20% over the next five years, compared to 34.83% over the past 5-year period.
Looking at the support for the MTEM, a number of firms have released research notes about the stock. BofA Securities stated their Buy rating for the stock in a research note on April 21, 2021, with the firm’s price target at $12. UBS coverage for the Molecular Templates Inc (MTEM) stock in a research note released on February 01, 2021 offered a Neutral rating with a price target of $13. Jefferies was of a view on September 08, 2020 that the stock is Buy, while Stifel gave the stock Buy rating on March 25, 2020, issuing a price target of $19. Barclays on their part issued Overweight rating on February 27, 2020.
